Cargando…
Ibrutinib response in cutaneous transformed lymphoplasmacytic lymphoma
Autores principales: | Lindholm, Kaleigh E., Forsberg, Peter A., Ewalt, Mark D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176001/ https://www.ncbi.nlm.nih.gov/pubmed/35844727 http://dx.doi.org/10.1002/jha2.253 |
Ejemplares similares
-
Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment
por: Schlevogt, Bernhard, et al.
Publicado: (2019) -
Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation
por: Quaglia, Francesca Maria, et al.
Publicado: (2019) -
Pseudo liposarcomatous plasma cells in a patient with liposarcoma and lymphoplasmacytic lymphoma
por: Schmidt, Adrian, et al.
Publicado: (2018) -
Rituximab use for lymphoplasmacytic lymphoma during continuous renal
replacement therapy
por: Simões, Marco, et al.
Publicado: (2019) -
Transformed lymphoplasmacytic lymphoma involving the main carina: A case report
por: NAKAO, MAKOTO, et al.
Publicado: (2013)